When designing nanomedicines to deliver therapeutics to diseased tissues, researchers face a fundamental hurdle: how do you get a drug to accumulate precisely where it is needed without harming healthy organs? While active targeting relies on engineering surface ligands to bind to specific cellular receptors, a powerful alternative relies entirely on physics and anatomy.
By strategically optimizing the physical dimensions of a nanoparticle, therapies can exploit the structural abnormalities of diseased tissues to accumulate passively. Understanding why this mechanism works requires looking closely at the intersection of vascular anatomy, physiological clearance mechanisms, and cellular mechanics.
The Anatomy of Passive Accumulation
In healthy tissues, the endothelial cells lining blood vessels are tightly packed, forming a secure barrier that keeps large molecules and particles contained within the bloodstream. However, when tissues undergo rapid, chaotic growth—such as solid tumors—or experience severe inflammation, this neat architecture breaks down.
To sustain rapid growth, tumors secrete signals that trigger the frantic creation of new blood vessels. This hurried angiogenesis results in highly irregular, defective vasculature characterized by large gaps or "fenestrations" between endothelial cells. As Guancheng Song et al. describe in their review of liposomal therapies, The Applications of Mitoxantrone and Its Liposome in Adult Acute Myeloid Leukemia, this structural leakiness allows nanomedicines to slip out of the bloodstream and into the malignant zone.
Healthy Vasculature: [Tight Junctions] -> Particles Contained
Tumor Vasculature: [Leaky Fenestrations] -> Particles Escape into Tissue
Once inside the diseased tissue, these particles remain trapped. Healthy tissues possess a functional lymphatic system that continuously drains excess fluid and returns it to circulation. Malignant tumors, however, typically feature impaired lymphatic drainage. As a single-author paper by Aditya Sengar explains in Precision in Practice: Nanotechnology and Targeted Therapies for Personalized Care, this combination of leaky blood vessels and broken drainage creates a one-way valve. Nanoparticles easily enter the tissue but cannot easily leave—a phenomenon widely known as the Enhanced Permeability and Retention (EPR) effect.
This passive mechanism is incredibly robust. In fact, Hiroyuki Hanada notes in Activities and Roles of a Bioventure Company established by the Basic Research and Technology in Academia that exploiting this physiological principle is a primary driver for improving the therapeutic index of modern micellar and liposomal drugs. The dominance of this structural leakage is so pronounced that Yuling Xiao argues in Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging that active targeting ligands can sometimes become redundant in vivo, as the physical leakiness of the tumor vasculature ultimately dictates where the nanocarriers settle.
The Biological Sieve: Finding the Goldilocks Zone
Passive targeting is entirely dependent on size. If a nanoparticle is too small, it escapes the body too quickly; if it is too large, the body's immune defense destroys it before it reaches its target. Optimizing a nanoparticle requires balancing these competing biological clearance pathways.
< 5.5 nm 50 nm - 150 nm > 200 nm
[Renal Clearance] <--- [Goldilocks Zone] ---> [Splenic/Hepatic Sequestration]
The Lower Bound: Renal Clearance
The human kidney acts as a physical sieve, constantly filtering small waste products out of the blood. The threshold for this filtration is incredibly sharp: molecules with a hydrodynamic diameter below roughly 5.5 to 6.5 nanometers are rapidly cleared through the urine.
To avoid immediate excretion and extend circulation time, nanoparticles must be engineered above this threshold. For instance, Ani Baghdasaryan et al. demonstrate in Phosphorylcholine-conjugated gold-molecular clusters improve signal for Lymph Node NIR-II fluorescence imaging in preclinical cancer models that keeping diagnostic particles intentionally below this threshold is useful for rapid clearance to prevent long-term liver accumulation. Conversely, when long-term therapeutic action is required, the authors of Renal clearable nanochelators for iron overload therapy show that tuning the diameter to sit precisely at or just above this filtration boundary balances the need for a prolonged therapeutic window with the requirement for safe, eventual elimination.
The Upper Bound: Hepatic and Splenic Sequestration
If making particles larger prevents them from washing out through the kidneys, why not make them as large as possible? The answer lies in the liver and spleen, which house specialized immune cells called macrophages. These cells act as the body's security guards, swallowing up large foreign objects via phagocytosis.
Particles larger than 150–200 nanometers are highly susceptible to being recognized and sequestered by these organs. Jie Meng et al. demonstrate in Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo that engineering nanocarriers to a tight diameter of approximately 50 nm strikes an ideal balance: they are large enough to avoid renal filtration, yet small enough to evade macrophage uptake in the liver and spleen, allowing them to remain in circulation long enough to exploit leaky tumor vessels.
The Trade-off: Accumulation vs. Deep Penetration
Even within the safe window of 200 nanometers, a secondary trade-off exists between how much of a drug accumulates at the tumor site versus how deeply it can penetrate the dense tissue matrix.
Yi Ma et al. explored this dynamic in Optimizing molecular weight of octyl chitosan as drug carrier for improving tumor therapeutic efficacy, revealing that while larger nanocarriers accumulate heavily at the tumor boundary due to prolonged blood circulation, smaller particles are required to diffuse deeply into the dense core of a tumor mass. To navigate this paradox, the authors of Antimonene with two-orders-of-magnitude improved stability for high-performance cancer theranostics selected a "Goldilocks" size of 55 nm, optimizing the compromise between material stability and tissue penetration.
Cellular Internalization Mechanics
Once a nanoparticle successfully navigates the bloodstream and leaks into the target tissue, it faces its final challenge: convincing the target cells to swallow it. This step introduces another layer of size-dependent physics.
Cells internalize external objects by wrapping their outer membrane around the particle and pinching it off into an internal vesicle. This process requires energy. As Xiao Zhang et al. show through molecular simulations in Simulation of nanoparticles interacting with a cell membrane: probing the structural basis and potential biomedical application, nanoparticle internalization efficiency is highly non-linear. If a particle is too small, it cannot generate enough thermodynamic driving force to bend the cell membrane. If it is too large, the energetic cost of deforming the membrane to wrap around the massive particle becomes too high.
Furthermore, different sizes trigger entirely different cellular ingestion pathways:
- Macropinocytosis: Morag R. Hunter et al. discovered in Understanding Intracellular Biology to Improve mRNA Delivery by Lipid Nanoparticles that increasing the size of lipid nanoparticles to roughly 120 nm shifts their uptake mechanism toward macropinocytosis, resulting in a massive 6.3-fold increase in intracellular mRNA delivery efficiency in vitro.
- Pinocytosis: Conversely, Jin-Hua Gao et al. demonstrate in Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation that engineering particles to a specific 150–160 nm range allows them to exploit endothelial pinocytosis, providing a physical pathway to cross the notoriously restrictive blood-brain barrier.
- Macrophage Internalization: When the goal is to intentionally deliver drugs to immune cells rather than evade them, Jing Qin et al. show in Exploiting macrophages as targeted carrier to guide nanoparticles into glioma that particles in the 100–200 nm range exhibit optimal internalization by macrophages, allowing these immune cells to act as cellular vehicles that carry the therapy across biological barriers.
Beyond Oncology: Inflammation-Mediated Targeting
While the EPR effect was originally discovered in cancer research, the underlying physical principles apply to any pathology characterized by dysfunctional, leaky vasculature. Chief among these is inflammation.
When tissue becomes inflamed—whether due to an infection, an autoimmune flare-up, or a cardiovascular crisis—immune cells release signaling molecules that cause local blood vessels to dilate and become porous. This allows defensive white blood cells to rush to the site, but it also opens the door for size-optimized nanoparticles to accumulate passively.
Cardiovascular Disease and Plaque Imaging
In advanced cardiovascular disease, arterial plaques become highly inflamed and unstable. Menglin Wu et al. highlight in Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications that this localized vascular dysfunction allows nanoparticles to passively concentrate inside vulnerable plaques. This concentration significantly boosts the contrast-to-noise ratio for diagnostic imaging without requiring complex active targeting chemistry.
However, getting inside a plaque requires navigating a dense fibrous cap. To solve this, Chengxi Wu et al. note in Advances in treatment strategies based on scavenging reactive oxygen species of nanoparticles for atherosclerosis that particles must be kept strictly below 40 nanometers to effectively infiltrate these dense pathological walls and deliver reactive oxygen species (ROS) scavengers directly to the core of the disease.
Systemic Inflammatory Conditions
This same mechanism allows for targeted delivery in other inflammatory conditions, such as arthritis and tissue infarction:
- Rheumatoid Arthritis: Huiyi Liang et al. demonstrate in Cationic nanoparticle as an inhibitor of cell-free DNA-induced inflammation that cationic nanoparticles naturally home in on inflamed joints due to localized vascular leakiness, concentrating the therapeutic effect where inflammation is highest.
- Myocardial Infarction: Following a heart attack, the damaged cardiac tissue becomes highly permeable. Aixia Xu et al. show in Fabrication of apigenin and adenosine-loaded nanoparticles against doxorubicin-induced myocardial infarction by reducing inflammation and oxidative stress that PLGA nanocarriers naturally concentrate in these injured zones at much higher levels than free-form drugs, protecting the heart from oxidative stress.
- Acute Organ Injury: The authors of Silk-engineered bioactive nanoparticles for targeted alleviation of acute inflammatory disease via macrophage reprogramming successfully leveraged this increased vascular permeability to achieve passive accumulation at injury sites in both acute lung injury (ALI) and acute kidney injury (AKI), proving that precise physical engineering can bypass the need for complex surface ligands across a wide array of human diseases.
Key Foundational Work
Liposomal Quercetin Efficiently Suppresses Growth of Solid Tumors in Murine Models (2006) — contributed 2 concept elements to this direction.
Characterization of Deposition from Nasal Spray Devices Using A Computational Fluid Dynamics Model of The Human Nasal Passages (2007) — contributed 1 concept elements to this direction.